Menu
Search
|

Menu

Close
X

Novavax Inc NVAX.OQ (NASDAQ Stock Exchange Global Select Market)

2.34 USD
+0.18 (+8.33%)
As of Feb 16
chart
Previous Close 2.16
Open 2.25
Volume 4,469,500
3m Avg Volume 1,308,000
Today’s High 2.52
Today’s Low 2.21
52 Week High 2.52
52 Week Low 0.73
Shares Outstanding (mil) 313.62
Market Capitalization (mil) 733.86
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
21
FY16
15
FY15
36
EPS (USD)
FY17
-0.467
FY16
-1.034
FY15
-0.593
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
28.05
8.57
Price to Book (MRQ)
vs sector
--
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
--
15.12
LT Debt to Equity (MRQ)
vs sector
--
11.85
Return on Investment (TTM)
vs sector
-58.50
13.54
Return on Equity (TTM)
vs sector
--
14.80

EXECUTIVE LEADERSHIP

James Young
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Stanley Erck
President, Chief Executive Officer, Interim Chief Financial Officer, Director, Since 2017
Salary: $618,000.00
Bonus: --
Gregory Glenn
President, Research and Development, Since 2016
Salary: $441,250.00
Bonus: --
John Herrmann
Senior Vice President, General Counsel, Corporate Secretary, Since 2014
Salary: $335,000.00
Bonus: --
John Trizzino
Senior Vice President - Commercial Operations, Since 2014
Salary: $359,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

20 Firstfield Rd
GAITHERSBURG   MD   20878-1760

Phone: +1240.2682000

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

SPONSORED STORIES